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Stem cells mainly include embryonic stem
cells (ESC), pluripotent stem cells (iPS),
Epiblast-derived stem cells (Epi-SC), and
adult tissue stem cells. ESC are pluripo-
tent, being able to differentiate into
the ectoderm, mesoderm and endoderm
(Evans and Kaufman, 1981; Martin, 1981).
However, there are ethical issues when
using human embryos, and ESC trans-
plants into mouse models can result in
malignant tumors. Further challenges fac-
ing research in the use of ESC are how to
reduce contamination, and prevent can-
cer risk. Human ESC lines derived from
single blastomeres have been reported
(Klimanskaya et al., 2006). This method
may create new stem cell lines and ther-
apies without destroying embryos, and
would thus address the ethical concerns
and allow the generation of matched tis-
sues for children and siblings born from
transferred preimplantation genetic diag-
nosis embryos. Another current challenge
is that the cells used in research are
rejected by the recipient’s immune sys-
tem. Yamanaka et al. reported the induc-
tion of iPS from mouse embryonic and
adult fibroblast cultures by introducing
four factors: Oct3/4, Sox2, c-Myc, and
Klf4 (Takahashi and Yamanaka, 2006).
Inducing pluripotent cells directly from
the patient’s own cells to generate tissue
or cells may resolve some of the prob-
lems associated with using ESC, including
the problems of immunorejection and the
ethical issues. However, the low frequency
of iPS cell derivation is still unresolved.
A major difficulty that scientists continue
to encounter is the identification of stem
cells in adult tissues. EpiSCs are derived
from post-implantation mouse embryos
from embryonic day 5.5 to E7.5 (Brons
et al., 2007). They show pluripotency
and require Nodal-Activin and fibroblast
growth factor signaling for maintenance
of this characteristic. Therefore, they are
considered to be more closely related to
human ESC than to mouse ESC (Tesar
et al., 2007). Adult stem cells such as
bone marrow stem cells, intestinal stem
cells (Van Der Flier and Clevers, 2009),
endothelial stem cells (Rafii, 2000), and
neural stem cells (Lewis, 1968) have been
detected in tissues. One challenge facing
researchers is how to control and reg-
ulate the process to successfully trigger
differentiation into the desired cell type
after the stem cells have been isolated.
When some defined transcription factors
are transferred into somatic cells, somatic
cells can directly reprogram to differenti-
ate into other cell types without passing
through a pluripotent state. Some reports
demonstrated that mouse fibroblasts can
directly reprogram to neural stem cells
(Han et al., 2012), cardiomyocytes (Ieda
et al., 2010), bipotencial hepatic stem cells
(Yu et al., 2013), and endothelial cells (Li
et al., 2013). However, the restricted prolif-
erative and lineage potential of the result-
ing cells limits the scope of their potential
applications.
Stem cell treatments include new tech-
nologies and therapies that aim to replace
damaged tissues and cells in order to treat
disease or injury (Lindvall and Kokaia,
2006). Stem cells have the power to
congregate in these damaged areas and
generate new cells and tissues by perform-
ing a repair and renewal process, restoring
functionality. ESC, iPS, and adult stem
cell therapies, which include bone mar-
row stem cells and peripheral stem cells
are currently being investigated or used
to treat a range of diseases. Bone mar-
row stem cells are used to replace blood
cells in people suffering from leukemia and
other cancers (Goldman et al., 1988). Burn
victims are also benefiting from stem cell
therapy, which allows for new skin cells to
be grafted as a replacement for those that
have been damaged (Janes et al., 2002).
The ability of stem cells to self-renew
and their capacity for differentiation offers
significant potential for the generation of
tissues with minimal risk of rejection and
side effects. A number of stem cell thera-
pies are still in the experimental stages, and
are controversial (Francis et al., 2013). The
first challenge researchers face when con-
sidering stem cell treatment is to under-
stand the mechanisms by which stem
cells function in the injured microenvi-
ronment using animal models, and then
to translate the results of these studies
to humans. Another challenge is how to
identify and isolate stem cells from tissue,
and then induce their differentiation into
the desired cell types. The third challenge
is how to prevent immunorejection after
stem cell transplantation. Immunological
rejection is a major barrier to success-
ful stem cell transplantation. A person’s
immune system may also recognize the
transplanted cells as foreign bodies and
this can trigger an immune reaction that
results in the rejection of the transplanted
cells. Recipients of the transplant usually
have to take strong immunosuppressive
drugs to reduce the chances of rejec-
tion but these drugs induce infection by
viruses or microbes in the environment
(van Sandwijk et al., 2013).
The goal of Stem Cell Treatments is
to publish all findings and experiences of
stem cell treatments, experimentally and
clinically, and to open up new possibilities
for the treatment of various diseases such
as Alzheimer’s disease, traumatic brain
injury, heart disease, diabetes, and can-
cer, etc., that we may promote health and
extend the human life span.
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